Featured news

Asimov Announces Cell Line Development Partnership with Kaigene to Advance Multispecific Antibody for Autoimmune Disease

Kyungdong Pharmaceutical and Asimov Announce Completion of Cell Line Development Campaign for Biosimilar Antibody

Asimov Joins the Genesis Mission, Using Boston University's NSF-Backed Cloud Lab to Power Lab-in-the-Loop AI Models

Asimov Launches Chrysalis Transposase, a Wholly-Owned Genome Integration Tool for Biotherapeutics Production

Asimov Announces Strategic Partnership with the Rosalind & Morris Goodman Cancer Institute at McGill University to Advance Next-Generation Biologics

Asimov Completes Lead Optimization Campaign with Mabylon AG to Advance Trispecific Antibody for Tree Pollen Allergies

Asimov Launches RNA Edge, a Lab-in-the-Loop Platform for AI Optimization of RNA Therapeutic Candidates

Asimov Announces Cell Line Development Partnership with Score Pharma to Advance Biosuperior Antibody Therapeutics

Asimov and AGC Biologics Team Up to Provide a Cost-Effective, Simplified, and Secure Manufacturing Approach for Viral Vector Production

Asimov Launches CHO Edge Rapid Pools to Bridge Biologics Discovery and CMC with Predictive Stable Expression

Optimizing Bispecific Antibody Expression with Amgen

Asimov Launches Stable AAV Producer Cell Lines, Setting a New Standard for Viral Vector Manufacturing